MedTrace Logo

ESCUDDO Long Term Follow Up

NCT07706673 · Status: ENROLLING_BY_INVITATION · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 13700

Last updated 2026-09-01

No results posted yet for this study

Summary

This phase IV trial evaluates the long term protection provided by either one or two doses of the 9v human papillomavirus (HPV) vaccine for participants who were part of the ESCUDDO study.

Conditions

  • Human Papillomavirus Infection
  • Human Papillomavirus-Related Malignant Neoplasm

Interventions

BIOLOGICAL

Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed

Given IM in ESCUDDO (NCT03180034)

BIOLOGICAL

Recombinant Human Papillomavirus Nonavalent Vaccine

Given intramuscularly (IM) in ESCUDDO (NCT03180034)

Sponsors & Collaborators

  • Merck Sharp and Dohme LLC

    collaborator UNKNOWN

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Aimee Kreimer · National Cancer Institute (NCI)

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-11
Primary Completion
2030-10-01
Completion
2031-01-15
FDA Drug
Yes

Countries

  • Costa Rica

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07706673 on ClinicalTrials.gov